Gudmundsson T E, Högberg T, Alm P, Anderson H, Baldetorp B, Fernö M, Långström E, Killander D
Department of Oncology, University Hospital, Lund, Sweden.
Acta Oncol. 1995;34(6):803-12. doi: 10.3109/02841869509127190.
DNA ploidy and S-phase fraction (SPF) were determined by flow cytometry on paraffin-embedded tumor material from 243 patients treated during 1980-1985. Patients with well differentiated and moderately differentiated tumors without solid areas (n = 351) formed a low-risk group (corrected 5-year survival 90%). Twenty-four patients, dead of disease within 5 years, were compared with 52 survivors. The estimated death risk was higher for those with SPF > or = 8.0% compared with those with SPF < 8.0% (odds ratio = 18.2; p < 0.001). SPF was the only independent prognostic factor in a multivariate analysis also including age, clinical stage and grade of differentiation. Patients with moderately differentiated tumors with solid areas or poorly differentiated tumors (n = 208) were regarded as a high-risk group. There was a difference in survival according to ploidy; the corrected 5-year survival was 75% for 106 patients with diploid tumors compared with 44% for those with non-diploid tumors (p < 0.0001). In a multivariate analysis DNA ploidy, age and clinical stage were independent prognostic factors, whereas SPF was no longer significant. Thus, DNA ploidy and SPF have different prognostic values depending on histological grade of endometrial carcinoma.
采用流式细胞术对1980 - 1985年期间接受治疗的243例患者石蜡包埋肿瘤组织的DNA倍体和S期细胞分数(SPF)进行了测定。肿瘤分化良好且中等分化且无实性区域的患者(n = 351)构成低风险组(校正5年生存率90%)。将24例5年内死于疾病的患者与52例幸存者进行比较。与SPF < 8.0%的患者相比,SPF≥8.0%的患者估计死亡风险更高(优势比 = 18.2;p < 0.001)。在一项多变量分析中,SPF是唯一的独立预后因素,该分析还包括年龄、临床分期和分化程度。中等分化有实性区域或低分化肿瘤的患者(n = 208)被视为高风险组。根据倍体情况生存率存在差异;106例二倍体肿瘤患者的校正5年生存率为75%,而非二倍体肿瘤患者为44%(p < 0.0001)。在多变量分析中,DNA倍体、年龄和临床分期是独立的预后因素,而SPF不再具有显著性。因此,根据子宫内膜癌的组织学分级,DNA倍体和SPF具有不同的预后价值。